과제정보
This research was supported from the Korean Cardiac Research Foundation (202002-02) and Korean Heart Rhythm Society (KHRS2020-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
참고문헌
- Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G, Brugada R. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1046-59.
- Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010;7:549-58.
- Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006;29:1130-59.
- Szel T, Antzelevitch C. Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. J Am Coll Cardiol 2014;63:2037-45.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018;138:e272-391.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126.
- Yang BF, Li YR, Xu CQ, et al. Mechanisms of artemisinin antiarrhythmic action. Chin J Pharm Toxicol 1999;13:169-75.
- Yang BF, Luo DL, Bao LH, Zhang YC, Wang HZ. Artemisinin blocks activating and slowly activating K+ current in guinea pig ventricular myocytes. Acta Pharmacologica Sinica 1998;19:269-72.
- So EC, Wu SN, Wu PC, Chen HZ, Yang CJ. Synergistic inhibition of delayed rectifier K+ and voltage-gated Na+ currents by artemisinin in pituitary tumor (GH3) cells. Cell Physiol Biochem 2017;41:2053-66.
- Qiao G, Li S, Yang B, Li B. Inhibitory effects of artemisinin on voltage-gated ion channels in intact nodose ganglion neurones of adult rats. Basic Clin Pharmacol Toxicol 2007;100:217-24.
- Di Diego JM, Sicouri S, Myles RC, Burton FL, Smith GL, Antzelevitch C. Optical and electrical recordings from isolated coronary-perfused ventricular wedge preparations. J Mol Cell Cardiol 2013;54:53-64.
- Fish JM, Welchons DR, Kim YS, Lee SH, Ho WK, Antzelevitch C. Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006;113:1393-400.
- Gurabi Z, Koncz I, Patocskai B, Nesterenko VV, Antzelevitch C. Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. Circ Arrhythm Electrophysiol 2014;7:134-42.
- Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-6.
- Wilde AA, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol 2010;49:543-53.
- Yoon N, Jeong HK, Lee KH, Park HW, Cho JG. Right ventricular longitudinal conduction delay in patients with Brugada syndrome. J Korean Med Sci 2021;36:e75.
- Lambiase PD, Ahmed AK, Ciaccio EJ, et al. High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation 2009;120:106-17, 1-4.
- Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011;123:1270-9.
- Malhi N, Cheung CC, Deif B, et al. Challenge and impact of quinidine access in sudden death syndromes: a national experience. JACC Clin Electrophysiol 2019;5:376-82.
- Andorin A, Gourraud JB, Mansourati J, et al. The QUIDAM study: hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm 2017;14:1147-54.
- Behr ER, Ben-Haim Y, Ackerman MJ, Krahn AD, Wilde AA. Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway? Eur Heart J 2021;42:1073-81.
- Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985;228:1049-55.
- Di Diego JM, Sun ZQ, Antzelevitch C. I(to) and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol 1996;271:H548-61.
- Di Diego JM, Patocskai B, Barajas-Martinez H, et al. Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. PLoS One 2020;15:e0242747.
- Giudicessi JR, Ye D, Tester DJ, et al. Transient outward current Ito gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011;8:1024-32.
- Litovsky SH, Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res 1990;67:615-27.
- Szel T, Koncz I, Antzelevitch C. Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm 2013;10:1720-7.
- Li GR, Wang HB, Qin GW, et al. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation 2008;117:2449-57.
- Patocskai B, Yoon N, Antzelevitch C. Mechanisms underlying epicardial radiofrequency ablation to suppress arrhythmogenesis in experimental models of Brugada syndrome. JACC Clin Electrophysiol 2017;3:353-63.